IRIS
FOGARI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.229
EU - Europa 1.677
AS - Asia 1.298
SA - Sud America 6
OC - Oceania 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.216
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.204
CN - Cina 1.173
IE - Irlanda 491
UA - Ucraina 428
FI - Finlandia 245
DE - Germania 236
SE - Svezia 113
SG - Singapore 102
IT - Italia 82
GB - Regno Unito 38
CA - Canada 24
RU - Federazione Russa 10
IN - India 8
ES - Italia 7
FR - Francia 6
IR - Iran 5
NL - Olanda 5
BE - Belgio 3
CO - Colombia 3
BR - Brasile 2
HU - Ungheria 2
JP - Giappone 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PL - Polonia 2
RO - Romania 2
TR - Turchia 2
AT - Austria 1
AU - Australia 1
BH - Bahrain 1
CH - Svizzera 1
EU - Europa 1
GR - Grecia 1
KG - Kirghizistan 1
LV - Lettonia 1
MK - Macedonia 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 5.216
Salva come PNG Salva come JPEG
Città #
Jacksonville 537
Dublin 491
Chandler 444
Nanjing 344
Boardman 162
Nanchang 157
Ashburn 128
Shenyang 119
Hebei 117
Princeton 102
Wilmington 102
Lawrence 98
Medford 94
Changsha 93
Jiaxing 70
Hangzhou 69
Beijing 61
Singapore 56
Tianjin 56
Helsinki 48
Seattle 24
Shanghai 21
Toronto 21
Woodbridge 19
Milan 17
Norwalk 15
Fairfield 12
Ann Arbor 9
Des Moines 9
Genova 9
Jinan 9
Bruino 8
Kunming 7
Los Angeles 6
New York 6
Ningbo 6
Washington 6
Lanzhou 5
Alcobendas 4
Eindhoven 4
Kochi 4
Pune 4
Verona 4
Bogotá 3
Bologna 3
Bruchsal 3
Brussels 3
Fuzhou 3
Saint Petersburg 3
Zhengzhou 3
Budapest 2
Changchun 2
Guangzhou 2
Houston 2
Leawood 2
Monza 2
Munich 2
Novokuznetsk 2
Orange 2
Parma 2
Pavia 2
Siena 2
Tappahannock 2
Ardabil 1
Auburn Hills 1
Auckland 1
Backa Topola 1
Bangkok 1
Bishkek 1
Bloomfield 1
Calgary 1
Changzhou 1
Dalby 1
Dourados 1
Düzce 1
Edmond 1
Ellsworth 1
Esfahan 1
Exeter 1
Falkenstein 1
Hazlet 1
Henagar 1
Issy-les-moulineaux 1
Jinhua 1
Kilburn 1
Las Vegas 1
Lima 1
Lodz 1
Manama 1
Manila 1
Menlo Park 1
Mexico City 1
Misinto 1
Mosgiel 1
Newark 1
Oklahoma City 1
Orzivecchi 1
Osaka 1
Ottawa 1
Paris 1
Totale 3.661
Salva come PNG Salva come JPEG
Nome #
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 126
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 79
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 78
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 78
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 75
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome 71
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus 71
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 71
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 70
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients 69
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 68
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 67
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 66
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 65
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 64
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 64
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 63
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 63
Adipocytokines levels in obese and non-obese subjects, an observational study 63
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 63
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 62
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome 62
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 61
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 60
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 60
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 60
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 60
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 59
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial 59
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 59
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 59
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 59
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 59
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 58
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 58
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 57
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 57
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 57
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 56
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 56
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 55
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 55
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 55
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 55
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 54
Effect of valsartan on insulin sensitivity, leptin, and BMI in hypertensive obese patients 54
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 54
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 53
Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients 53
Exenatide or glimepiride on insulin resistance in type 2 diabetic patients 52
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type2 diabetic patients not well controlled by metformin 52
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 51
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 51
Exenatide paragonato a glimepiride in aggiunta a metformina sul controllo glicemico, l’insulino-resistenza e i parametri infiammatori in pazienti diabetici di tipo 2 51
Variation of some inflammatory markers in hypertensive patients after one year of olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies. 51
Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study 51
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 51
Effetti di una combinazione di vildagliptin + metformina su alcuni parametri di funzionalità β-cellulare e di insulino-resistenza in uno studio a 12 mesi 50
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 50
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 50
Valutazione dei livelli delle metalloproteasi 2 e 9 e dei loro inibitori nella dislipidemia combinata durante terapia con acidi grassi polinsaturi 50
Effetti di sitagliptin rispetto a glibenclamide in aggiunta a metformina e pioglitazone in pazienti diabetici di tipo 2 50
Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared to olmesartan or amlodipine monotherapies 49
Effetti di acarbose sui parametri infiammatori e di insulino-resistenza durante un carico orale di grassi 49
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 48
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 48
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. 48
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation 48
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients 47
Una possibilità per migliorare il controllo glicemico e la funzionalità β-celllare durante tre anni di studio: la triplice terapia 47
Vildagliptin action on some adipocytokines levels in type 2 diabetic patients: a 12 months, placebo-controlled study 47
A randomized, double blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetic patients already treated with pioglitazone and metformin: a three years study 47
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients 47
Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction 46
Exenatide plus metformin compared to metformin alone on beta cell function in type 2 diabetic patients. 46
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 46
Modificazioni ultrasonografiche del tessuto adiposo viscerale e sottocutaneo dopo terapia con pioglitazone o glibenclamide in combinazione con rosuvastatina in pazienti diabetici di tipo 2 non ben controllati da metformina 46
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 45
Variation of some inflammatory biomarkers after the addition of sitagliptin in type 2 diabetic patients not controlled by metformin 45
Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes 44
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. 43
Effetti di pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina dopo un carico orale di grassi 43
Studio randomizzato, in doppio cieco, placebo-controllato sugli effetti di sitagliptin sui parametri di insulino-resistenza e di funzionalità beta-cellulare. 42
Valutazione dei livelli di MMP-2, MPP-9 e dei loro inibitori nella iperlipemia combinata 42
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies 41
Valsartan improves plasma leptin in hypertensive obese patients 40
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 40
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial 40
Sitagliptin added to previously taken anti-diabetic agents on glycemic control and lipid profile 38
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 37
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 37
Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients 36
Efficacy of simvastatin and fenofibrate association in hypercholesterolemic, type 2 diabetic patients compared to monotherapy 33
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months 31
Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2 years study 31
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load 30
The effects of canrenone in patients with metabolic syndrome 26
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 24
Totale 5.257
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020252 0 0 0 0 0 0 7 88 0 123 34 0
2020/2021754 96 80 17 82 0 100 6 123 17 111 104 18
2021/2022366 0 0 18 3 3 3 2 25 21 2 58 231
2022/20231.364 130 93 1 91 161 150 0 90 571 17 40 20
2023/2024407 45 98 15 31 41 102 7 39 6 4 13 6
2024/2025274 10 105 43 48 27 30 11 0 0 0 0 0
Totale 5.257